ALAMERE Phase 2b EoE study
The ALAMERE clinical research study is examining an investigational drug, solrikitug, and its potential to alleviate symptoms and improve swallowing difficulties in adults (18-75 years) with eosinophilic esophagitis (EoE).
To learn more about participating in the study, please visit https://www.alamerestudy.com/
Trials are currently being conducted in:
Alabama
• Dothan
Arizona
• Peoria
• Tucson
California
• Inglewood
• San Diego
Florida
• Inverness
• Jacksonville
Idaho
• Boise
Iowa
• Iowa City
Kansas
• Topeka
Maryland
• Chevy Chase
Massachusetts
• Boston
Clinical Study for People with Eosinophilic Esophagitis
NexEos Bio is actively seeking volunteers for a clinical study focused on understanding and advancing diagnosis for eosinophilic esophagitis (EoE). If you are located in or near Salt Lake City, Philadelphia, or Chicago (USA) and have been diagnosed with EoE, NexEos Bio would love to hear from you.As a participant, you’ll be contributing to critical research aimed at improving diagnosis and monitoring options for EoE patients. The study will involve several visits, and participants will receive medical support and, in many cases, compensation for their time and participation.
What We're Looking For:
- Adults (18-65) diagnosed with eosinophilic esophagitis
- Those able to attend study visits in Salt Lake City, Philadelphia, or Chicago
If you're interested or know someone who might be, please email clinicaltrials.gov@nexeosdx.com for more details on how to join this important research effort. You can find more information about this clinical trial at https://clinicaltrials.gov/study/NCT05757856
Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects with Eosinophilic Esophagitis
This trial is being conducted to determine the safety and effectiveness of an FDA approved drug called Zemaira in adults with eosinophilic esophagitis (EoE). Participation may last up to 32 weeks.
Participants will be asked to:
⦁ Take IV infusions of the study drug weekly for 8 weeks
⦁ Answer questions related to their symptoms and quality of life
⦁ Provide blood and urine samples
⦁ Complete two standard of care endoscopies during the study
You may qualify if you:
⦁ Are between the ages of 18 and 70
⦁ Are experiencing active EoE with symptoms
⦁ Willing to maintain current dietary regimen
Participants will receive stipend and/or travel reimbursement for each study visit completed
Participants can maintain their current medication and dietary regimen
TO LEARN MORE ABOUT THIS STUDY
DOWNLOAD: Study flyer
EMAIL: lauren.turner@cchmc.com
CALL: 513-803-5446
Learn more about CEGIR and its work at rdcrn.org/cegir
The CROSSING study for adults and adolescents with EoE |
 | The CROSSING clinical research study is evaluating the safety and efficacy of tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients between 12 and 80 years of age.
To learn more about participating in the study you can visit the website https://eoetrialandyou.com/APFED or call 844-432-3890. |
A Study to Evaluate the efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Ages: 12-75 years old
Study Reference: NCT04753697 and CC-93538-EE-001
Study Type: Interventional
Location: Multiple locations in U.S.
Learn More
OMEGA-A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), Gastroenteritis (EGE) and Colitis (EC)
Ages: 3-65
Study Reference: NCT02523118
Study Type: Observational
Location: Multiple locations in U.S.
Learn more
Download the flyer
Phase 2 Study of Esophageal String Test in Eosinophilic Esophagitis
Ages: 7-65
Study Reference: NCT02008903
Study type: Observational
Location: Children’s Hospital Colorado (Aurora, CO); Lurie Children’s Hospital (Chicago, IL); Northwestern University (Chicago, IL)
Learn more
Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools
Ages: 5-80
Study Reference: NCT02453126
Study type: Observational
Location: Mayo Clinic, Rochester, MI
Learn more